Feasibility of improving patient’s safety with in vivo dose tracking in intracavitary and interstitial HDR brachytherapy

Alexandros G.Sfakianakis shared this article with you from Inoreader Feasibility of improving patient’s safety with <em>in vivo</em> dose tracking in intracavitary and interstitial HDR brachytherapy Μέσω Brachytherapy Publication date: Available online 10 November 2020 Source: Brachytherapy Author(s): Jessica Muenkel, Zhengzheng Xu, Bryan J. Traughber, Tanvir Baig, Keying Xu, Christian Langmack, Eleanor Harris, Tarun K. Podder View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

EyeDose: An open-source tool for using published Monte Carlo results to estimate the radiation dose delivered to the tumor and critical ocular structures for 125I Collaborative Ocular Melanoma Study eye plaques

Alexandros G.Sfakianakis shared this article with you from Inoreader EyeDose: An open-source tool for using published Monte Carlo results to estimate the radiation dose delivered to the tumor and critical ocular structures for <sup>125</sup>I Collaborative Ocular Melanoma Study eye plaques Μέσω Brachytherapy Publication date: Available online 10 November 2020 Source: Brachytherapy Author(s): Christopher L. Deufel, Sarah McCauley Cutsinger, Kimberly S. Corbin, Lauren A. Dalvin, Ivy A. Petersen View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Evidence for interleukin 17 involvement in severe immune-related neuroendocrine toxicity

Alexandros G.Sfakianakis shared this article with you from Inoreader Evidence for interleukin 17 involvement in severe immune-related neuroendocrine toxicity Μέσω European Journal of Cancer Publication date: December 2020 Source: European Journal of Cancer, Volume 141 Author(s): Luca Mazzarella, Silvia Giugliano, Paolo D'Amico, Carmen Belli, Bruno Achutti Duso, Maria Rescigno, Giuseppe Curigliano View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Non-coding RNA derived from extracellular vesicles in cancer immune escape: Biological functions and potential clinical applications

Alexandros G.Sfakianakis shared this article with you from Inoreader Non-coding RNA derived from extracellular vesicles in cancer immune escape: Biological functions and potential clinical applications Μέσω Cancer Letters Publication date: Available online 10 November 2020 Source: Cancer Letters Author(s): Mingyao Huang, Xueqiang Peng, Liang Yang, Shuo Yang, Xinyu Li, Shilei Tang, Bowen Li, Hongyuan Jin, Bo Wu, Jingang Liu, Hangyu Li View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Mitochondrial rewiring through mitophagy and mitochondrial biogenesis in cancer stem cells: A potential target for anti-CSC cancer therapy

Alexandros G.Sfakianakis shared this article with you from Inoreader Mitochondrial rewiring through mitophagy and mitochondrial biogenesis in cancer stem cells: A potential target for anti-CSC cancer therapy Μέσω Cancer Letters Publication date: Available online 10 November 2020 Source: Cancer Letters Author(s): Prakash Priyadarshi Praharaj, Debasna Pritimanjari Panigrahi, Chandra Sekhar Bhol, Srimanta Patra, Soumya Ranjan Mishra, Kewal Kumar Mahapatra, Bishnu Prasad Behera, Amruta Singh, Shankargouda Patil, Sujit Kumar Bhutia View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

PRMT6 deficiency induces autophagy in hostile microenvironment of hepatocellular carcinoma tumors by regulating BAG5-associated HSC70 stability

Alexandros G.Sfakianakis shared this article with you from Inoreader PRMT6 deficiency induces autophagy in hostile microenvironment of hepatocellular carcinoma tumors by regulating BAG5-associated HSC70 stability Μέσω Cancer Letters Publication date: Available online 11 November 2020 Source: Cancer Letters Author(s): Noélia Che, Kai-Yu Ng, Tin-Lok Wong, Man Tong, Phillis WF. Kau, Lok-Hei Chan, Terence K. Lee, Michael SY. Huen, Jing-Ping Yun, Stephanie Ma View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Modification of diet, exercise and lifestyle (MODEL) study: a randomised controlled trial protocol

Alexandros G.Sfakianakis shared this article with you from Inoreader Modification of diet, exercise and lifestyle (MODEL) study: a randomised controlled trial protocol Μέσω BMJ Open Current Issue Introduction Most cardiovascular disease (CVD)-related events could be prevented or substantially delayed with improved diet and lifestyle. Providing information on structural vascular disease may improve CVD risk factor management, but its impact on lifestyle change remains unclear. This study aims to determine whether providing visualisation and pictorial representation of structural vascular disease (abdominal aortic calcification (AAC)) can result in healthful diet and lifestyle change. Methods and analysis This study, including men and women aged 60–80 years, is a 12-week, two-arm, multisite randomised controlled trial. At baseline, all participants will have AAC assessed from a lateral spine image captured using a bone densitometer. Participants will then be randomised to receive their AAC results at baseline (intervention group) or a usual care control group that will receive their results at 12 weeks. All participants will receive information about routinely assessed CVD risk factors and standardised (video) diet and lifestyle advice with three simple goals: (1) increase fruit and vegetable (FV) intake by at least one serve per day, (2) improve other aspects of the diet and (3) reduce sitting time and increase physical activity. Clinical assessments will be performed at baseline and 12 weeks. Outcomes The primary outcome is a change in serum carotenoid concentrations as an objective measure of FV intake. The study design, procedures and treatment of data will adhere to Standard Protocol Items for Randomized Trials guidelines. Ethics and dissemination Ethics approval for this study has been granted by the Edith Cowan University and the Deakin University Human Research Ethics Committees (Project Numbers: 20513 HODGSON and 2019-220, respectively). Results of this study will be published in peer-reviewed academic journals and presented in scientific meetings and conferences. Information regarding consent, confidentiality, access to data, ancillary and post-trial care and dissemination policy has been disclosed in the participant information form. Trial registration number Australian New Zealand Clinical Trial Registry (ACTRN12618001087246). View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Awake prone positioning of hypoxaemic patients

Alexandros G.Sfakianakis shared this article with you from Inoreader Awake prone positioning of hypoxaemic patients with COVID-19: protocol for a randomised controlled open-label superiority meta-trial Μέσω BMJ Open Current Issue Introduction Prone positioning (PP) is an effective first-line intervention to treat patients with moderate to severe acute respiratory distress syndrome (ARDS) receiving invasive mechanical ventilation, as it improves gas exchanges and reduces mortality. The use of PP in awake spontaneous breathing patients with ARDS secondary to COVID-19 was reported to improve oxygenation in few retrospective trials with small sample size. High-level evidence of awake PP for hypoxaemic patients with COVID-19 patients is still lacking. Methods and analysis The protocol of this meta-trial is a prospective collaborative individual participant data meta-analysis of randomised controlled open label superiority trials. This design is particularly adapted to a rapid scientific response in the pandemic setting. It will take place in multiple sites, among others in USA, Canada, Ireland, France and Spain. Patients will be followed up for 28 days. Patients will be randomised to receive whether awake PP and nasal high flow therapy or standard medical treatment and nasal high flow therapy. Primary outcome is defined as the occurrence rate of tracheal intubation or death up to day 28. An interim analysis plan has been set up on aggregated data from the participating research groups. Ethics and dissemination Ethics approvals were obtained in all participating countries. Results of the meta-trial will be submitted for publication in a peer-reviewed journal. Each randomised controlled trial was registered individually, as follows: NCT04325906, NCT04347941, NCT04358939, NCT04395144 and NCT04391140. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Development of a risk prediction model of potentially avoidable readmission for patients hospitalised with community-acquired pneumonia: study protocol and population

Alexandros G.Sfakianakis shared this article with you from Inoreader Development of a risk prediction model of potentially avoidable readmission for patients hospitalised with community-acquired pneumonia: study protocol and population Μέσω BMJ Open Current Issue Introduction 30-day readmission rate is considered an adverse outcome reflecting suboptimal quality of care during index hospitalisation for community-acquired pneumonia (CAP). However, potentially avoidable readmission would be a more relevant metric than all-cause readmission for tracking quality of hospital care for CAP. The objectives of this study are (1) to estimate potentially avoidable 30-day readmission rate and (2) to develop a risk prediction model intended to identify potentially avoidable readmissions for CAP. Methods and analysis The study population consists of consecutive patients admitted in two hospitals from the community or nursing home setting with pneumonia. To qualify for inclusion, patients must have a primary or secondary discharge diagnosis code of pneumonia. Data sources include routinely collected administrative claims data as part of diagnosis-related group prospective payment system and structured chart reviews. The main outcome measure is potentially avoidable readmission within 30 days of discharge from index hospitalisation. The likelihood that a readmission is potentially avoidable will be quantified using latent class analysis based on independent structured reviews performed by four panellists. We will use a two-stage approach to develop a claims data-based model intended to identify potentially avoidable readmissions. The first stage implies deriving a clinical model based on data collected through retrospective chart review only. In the second stage, the predictors comprising the me dical record model will be translated into International Classification of Diseases, 10th revision discharge diagnosis codes in order to obtain a claim data-based risk model. The study sample consists of 1150 hospital stays with a diagnosis of CAP. 30-day index hospital readmission rate is 17.5%. Ethics and dissemination The protocol was reviewed by the Comité de Protection des Personnes Sud Est V (IRB#6705). Efforts will be made to release the primary study results within 6 months of data collection completion. Trial registration number ClinicalTrials.gov Registry (NCT02833259). View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Development and validity testing of the Adolescent Health Literacy Questionnaire (AHLQ): Protocol for a mixed methods study within the Irish school setting

Alexandros G.Sfakianakis shared this article with you from Inoreader Development and validity testing of the Adolescent Health Literacy Questionnaire (AHLQ): Protocol for a mixed methods study within the Irish school setting Μέσω BMJ Open Current Issue Introduction Health literacy research has focused predominantly on the adult population, and much less is understood about this concept from an adolescent perspective. The tools currently available to measure adolescent health literacy have been adapted from adult versions. This limits their applicability to young people because of the developmental characteristics that impact on adolescents' behaviour, including impulse control and judgement skills. This protocol describes the intended development and validity testing of a questionnaire to measure health literacy in adolescents. Methods and analysis This protocol describes this mixed methods study that has three phases: the first phase will involve grounded research with adolescents using qualitative group interviews, co-design and concept mapping workshops to understand what health and healthy behaviours mean to adolescents and to explore their health literacy needs and the potential domains for the questionnaire. The draft health literacy domains identified will be presented to the youth advisory panel, and the questionnaire will be altered based on their feedback. Cognitive pretesting of the questionnaire items will also be conducted. Phase 2 will involve piloting the questionnaire to a two-stage random sample of young people in five urban and rural schools in Ireland. Test–retest reliability will be conducted using Pearson correlation coefficient. Confirmatory factor analysis will also be conducted to analyse the psychometric properties of the questionnaire. Phase 3 will involve the questionnaire being rolled out to a n ationally representative sample of adolescents (n=6052) in Ireland to assess their levels of health literacy. Ethics and dissemination Ethical approval to conduct this study has been granted from the University College Dublin Human Research Ethics Committee – Sciences (LS-20–08). Informed assent from adolescents and informed consent from parents/guardians will be sought. The findings of this research will be disseminated at national and international conferences, as well as through publication in peer-reviewed journals. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Investigating a new tablet-based telerehabilitation app in patients with aphasia: a randomised, controlled, evaluator-blinded, multicentre trial protocol

Alexandros G.Sfakianakis shared this article with you from Inoreader Investigating a new tablet-based telerehabilitation app in patients with aphasia: a randomised, controlled, evaluator-blinded, multicentre trial protocol Μέσω BMJ Open Current Issue Introduction Aphasia is a common language disorder acquired after stroke that reduces the quality of life of affected patients. The impairment is frequently accompanied by a deficit in cognitive functions. The state-of-the-art therapy is speech and language therapy but recent findings highlight positive effects of high-frequency therapy. Telerehabilitation has the potential to enable high-frequency therapy for patients at home. This study investigates the effects of high-frequency telerehabilitation speech and language therapy (teleSLT) on language functions in outpatients with aphasia compared with telerehabilitative cognitive training. We hypothesise that patients training with high-frequency teleSLT will show higher improvement in language functions and quality of life compared with patients with high-frequency tele-rehabilitative cognitive training (teleCT). Methods and analysis This study is a randomised controlled, evaluator-blinded multicentre superiority trial comparing the outcomes following either high-frequency teleSLT or teleCT. A total of 100 outpatients with aphasia will be recruited and assigned in a 1:1 ratio stratified by trial site and severity of impairment to one of two parallel groups. Both groups will train over a period of 4 weeks for 2 hours per day. Patients in the experimental condition will devote 80% of their training time to teleSLT and the remaining 20% (24 min/day) to teleCT, vice versa for patients in the control condition. The primary outcome measure is the understandability of verbal communication on the Amsterdam Nijmegen Everyday Language Test and secondary outcome measures are intelligibility of the verbal communication, impairment of receptive and expressive language functions, confrontation naming. Other outcomes measures are quality of life and acceptance (usability and subjective experience) of the teleSLT system. Ethics and dissemination This study is approved by the Ethics Committee Bern (ID 2016-01577). Results will be submitted to a peer-reviewed journal. Trial registration number NCT03228264. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Discontinuing antidepressant medication after mindfulness-based cognitive therapy: a mixed-methods study exploring predictors and outcomes of different discontinuation trajectories, and its facilitators and barriers

Alexandros G.Sfakianakis shared this article with you from Inoreader Discontinuing antidepressant medication after mindfulness-based cognitive therapy: a mixed-methods study exploring predictors and outcomes of different discontinuation trajectories, and its facilitators and barriers Μέσω BMJ Open Current Issue Objectives This study aimed to explore predictors and outcomes associated with different trajectories of discontinuing antidepressant medication (ADM), in recurrently depressed individuals after participation in mindfulness-based cognitive therapy (MBCT). Facilitators and barriers of discontinuation were explored qualitatively. Design Mixed-methods study combining quantitative and qualitative data, drawn from a randomised controlled trial. Setting Twelve secondary and tertiary psychiatric outpatient clinics in the Netherlands. Participants Recurrently depressed individuals (N=226) who had been using ADM for at least 6 months and in partial or full remission. Regardless of trial condition, we made post-hoc classifications of patients' actual discontinuation trajectories: full discontinuation (n=82), partial discontinuation (n=34) and no discontinuation (n=110) of ADM within 6 months after baseline. A subset of patients (n=15) and physicians (n=7) were interviewed to examine facilitators and barriers of discontinuation. Interventions All participants were offered MBCT, which consisted of eight weekly sessions in a group. Primary and secondary outcome measures Demographic and clinical predictors of successful discontinuation within 6 months, relapse risk within 15 months associated with different discontinuation trajectories, and barriers and facilitators of discontinuation. Results Of the 128 patients assigned to MBCT with discontinuation, only 68 (53%) fully discontinued ADM within 6 months, and 17 (13%) discontinued partially. Predictors of full discontinuation were female sex, being employed and lower levels of depression. Relapse risk was lower after no discontinuation (45%) or partial discontinuation (38%), compared with full discontinuation (66%) (p=0.02). Facilitators and barriers of discontinuation were clustered within five themes: (1) pre-existing beliefs about depression, medication and tapering; (2) current experience with ADM; (3) life circumstances; (4) clinical support and (5) mindfulness. Conclusions Discontinuing antidepressants appears to be difficult, stressing the need to support patients and physicians in this process. MBCT may offer one of these forms of support. Trial registration number ClinicalTrials.gov Registry (NCT00928980); post-results. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.